Drugs / bimokalner
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06521190 Comparator | Dec 2023 → Mar 2025 overdue | platinum-induced ototoxicity | Acousia Therapeutics GmbH | Recruiting | No outcome recorded |
Press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bimokalner | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06521190 ↗ |
| Known as | ACOU085 | “Drug: ACOU085 (bimokalner)” NCT06521190 ↗ |
| Modality | Small molecule | — CHEMBL6068009 ↗ |
| Route | Other | “ACOU085 administered into the middle ear using 3 transtympanic injections per ear” NCT06521190 ↗ |